Increased CSF aquaporin-4, and interleukin-6 levels in dogs with idiopathic communicating internal hydrocephalus and a decrease after ventriculo-peritoneal shunting
© The Author(s) 2016
Received: 10 March 2016
Accepted: 30 May 2016
Published: 29 June 2016
Studies in animal models, in which internal hydrocephalus has been induced by obstructing the cerebrospinal fluid pathways, have documented an up-regulation of the concentrations of aquaporin-4 (AQP4) in the brain. In this study, the concentrations of aquaporin-1 (AQP1), AQP1, AQP4 and interleukin-6 (IL-6) were determined in the CSF of dogs with idiopathic communicating hydrocephalus before and after the reduction of intraventricular volume following ventriculo-peritoneal shunt (VP-shunt) treatment.
The concentrations of AQP4 and IL-6 were increased in the cerebrospinal fluid of dogs with hydrocephalus compared to controls. Both parameters significantly decreased after surgical treatment, accompanied by decrease of ventricular size and the clinical recovery of the dogs. AQP1 was not detectable in CSF.
Brain AQP4 up-regulation might be a compensatory response in dogs with hydrocephalus. Future determination of AQP4 at the mRNA and protein level in brain tissue is warranted to substantiate this hypothesis.
KeywordsAquaporin Communicating hydrocephalus Dogs Interleukin-6
Definitive treatment options for internal hydrocephalus in dogs and humans rely mostly on surgical implantation of CSF-draining shunt systems [1–4]. Medical treatment methods aiming at reducing CSF production have been reported to provide temporary relief of clinical signs, but are mostly ineffective [2, 5–7]. Therefore, improved medical treatment options, especially for immature hydrocephalic patients, are desirable. Aquaporins (AQPs) are a family of water channel proteins, which are found in cell membranes in a number of tissues, including the central nervous system (CNS) [8, 9]. In the brain, the predominant water channel is AQP4, which provides the molecular basis for bidirectional water transport across the cell membranes of the blood–brain- and blood-CSF boundaries. The driving force behind water movement can be both osmotic and hydraulic in nature, the latter allowing the bulk flow of water across cell membranes [9–11]. AQP4 is mainly located in the astrocyte foot processes that surround capillaries in the CNS. At this boundary, brain AQP4 regulates water removal from the pericapillary space into brain vessels suggesting it has a crucial role in fluid volume homeostasis [8–11].
Under certain pathological conditions changes in AQP4 expression have been found [12–14]. Studies in animal models, in which internal hydrocephalus has been induced by injection of kaolin into the subarachnoid space, documented an up-regulation of AQP4 in the periventricular white matter [15, 16] and cerebral cortex . Increased levels of soluble AQP4 were also found in the CSF of children with naturally occurring internal hydrocephalus . It has been suggested that increased integration of AQP4 into the astrocyte membranes might have a compensatory effect in countering excess CSF [15, 19, 20] by increased astroglial clearance of excess brain water by transcellular routes and/or through the glia limitans .
A second water channel in the CNS, namely AQP1, is reported to be limited to choroid plexus epithelia within the CNS. Experimental depletion of the AQP1 gene in mice leads to a decrease in CSF production by the choroid plexus, demonstrating a role for AQP1 in CSF production . The proposed adaptive and protective roles of AQP1 and-4 as regulators of CSF production and absorption in the pathophysiology of hydrocephalus, establishes these AQPs as interesting candidates for possible treatment options. Interleukin 6 (IL-6) is a pro-inflammatory cytokine. Increased levels of IL-6 have been associated with periventricular white matter damage . Neurons, astrocytes, microglia and endothelial cells are the main sources of IL-6 in the CNS . Internal hydrocephalus is primarily a white matter disease and IL-6 levels may be used as a surrogate marker for white matter injury. Thus, a correlation between IL-6 and AQP4 levels could be useful to indicate the extent of white matter damage.
The aim of the present study was to determine the concentration of AQP1and AQP4 in the CSF of dogs with idiopathic communicating hydrocephalus, and possible changes in these levels after reduction of intra-ventricular pressure following ventriculo-peritoneal shunting. Given the previously-reported relationship between IL-6 and white matter damage in neonatal children and the presence of white matter damage in internal hydrocephalus, we also investigated the relationship between IL-6 and the aquaporins. We hypothesised that increased ventricular volume is positively correlated to CSF levels of AQP4 and IL-6, and negatively correlated to AQP1 in dogs with idiopathic communicating hydrocephalus.
Fourteen dogs with internal hydrocephalus, whose owners decided on surgical implantation of a ventriculo-peritoneal shunt (VP-shunt) system for permanent CSF drainage were prospectively selected between 2010 and 2014. The dogs had to meet the following criteria to be included in the study. (1) The hydrocephalus had to be diagnosed as idiopathic communicating, based on magnetic resonance imaging (MRI) of the brain without signs of parenchymal contrast enhancement or visual obstruction of CSF pathways. (2) Clinical re-evaluation, with CSF samples taken and immediately stored at −80 °C and both pre- and post-operative MRIs performed in our clinic to allow direct comparisons. (3) Medical pre-treatment using drugs to reduce CSF production (glucocorticoids, omeprazole, acetazolamide, furosemide) excluded dogs from the study. (4) In the follow up MRI, a decrease in ventricular volume had to be demonstrated as an indication for effective shunt treatment.
CSF collection and MRI examination was also performed on a control group of 10 dogs that were donated to the clinic after euthanasia due to non-neurological diseases. CSF was taken within 2 min of death of the animals. Ventriculomegaly was an exclusion criterion for the dogs in this group.
Collected data included the breed, age, gender, body-weight, type and duration of neurological deficits before and after surgery. Clinical data regarding the presenting signs and clinical improvement of the animals after shunting procedures were determined by a board certified neurologist. A standardised neurologic examination was performed prior to, and every day after surgery until discharge, and again 3 months after surgery.
Magnetic resonance imaging
Diagnosis of idiopathic communicating hydrocephalus was made by MRI using a 1.0 Tesla scanner (Gyroscan Intera, Phillips, Hamburg, Germany) and a solenoid surface coil (C3). For the MRI examination dogs were premedicated with diazepam (0.5 mg/kg IV) and l-methadone (0.5 mg/kg IV). Anesthesia was induced with propofol (4 mg/kg IV) and maintained after endotracheal intubation with isoflurane in oxygen. Sagittal, dorsal, and transverse T2-weighted, transverse FLAIR sequences, T1-weighted before and after intravenous administration of 0.2 mL/kg gadodiamide (Omniscan®) were acquired in all animals pre-operatively. The administration of a contrast agent was of course not feasible in the post-mortem scans in the control dogs but was useful to exclude other neurological diseases in the study group. T2-weighted transverse images of the head were chosen from the whole MR-dataset for image segmentation, using T2-Turbospin echo sequences (TE: 120 ms, TR: 2900 ms). Slice thickness varied from 2–3 mm. The field of view measured 180 × 180 mm in small dogs and 210 × 210 mm in large dogs. The matrix was 288 × 288 in small dogs and 384 × 384 in large dogs leading to an in-plane pixel size between 0.625 × 0.625 and 0.54 × 0.54 mm.
On the day of the diagnostic MRI, a routine CSF examination was performed (cytology and biochemical analysis) to rule out inflammatory diseases of the brain. CSF was collected from the cisterna magna (1 mL per 5 kg body weight).
The first CSF specimen for AQP and IL-6 analysis was collected from the pumping chamber during VP-shunt placement. After insertion of the ventricular catheter and connection of the pumping chamber, CSF was allowed to exit the ventricles via the shunt until pulsatile flow was observed in the transparent chamber. Depending on the ventricular volume and the size of the dog, 1–2 mL CSF was collected and stored in plastic tubes (Eppendorf tubes) at −80 °C for further analyses. The ventricular catheter was routinely tested for patency: 3 h after emptying the chamber via transcutaneous puncture, the chamber was checked for refilling by repeat puncture. The second CSF specimen was collected 3 months after shunt insertion from the subcutaneous pumping chamber.
Approval by an ethics committee for the CSF collection was not required as all procedures are part of the therapeutic procedure or routine diagnostic workup of clinical patients [German Animal Experiment Act [“Tierschutzgesetz”], paragraph 9.2]. Verbal approval to examine the CSF for research purposes was obtained from the owners.
CSF AQP1, AQP4, and IL-6 measurements
Frozen CSF specimens were evaluated 4–26 months after sampling. A dog-specific ELISA Kit was used for analyses of AQP1 and AQP4 in CSF, according to the instructions provided by the manufacturer (Canine AQP ELISA kit, assay ID AQP4: E08A0467; AQP1: E08A0863, BlueGene Biotech, Shanghai, China). The kit applied the competitive immunoassay technique using a monoclonal anti-AQP4-antibody and an AQP4 horseradish- peroxidase conjugate. Standards containing 0, 2.5, 5.0, 10, 25 and 50 ng/mL AQP4 were used to create a standard curve, which was used to calculate AQP4 concentrations in the biological samples. According to the manufacturer’s instructions no significant cross-reactivity or interference between AQP4 and its analogues was observed. The coefficient of variation within a given lot and between different lots was stated to be less than 10 %. Samples were determined in duplicate and the detection limit of the specific assay proved to be 0.1 ng/mL.
IL-6 concentrations were determined by a bioassay based on the dose-dependent growth stimulation of IL-6 on the B9 hybridoma cell line [27, 28]. This cell line requires IL-6 for survival and proliferation. The advantages of the B9 assay are its extreme sensitivity and its feature that only bioactive molecules are measured. The assay was performed in sterile, 96-well microtiter plates. In each well, 5000 B9 cells were incubated for 72 h with serial dilutions of biological samples (cerebrospinal fluid) or with different concentrations of a human IL-6 standard (code 89–548, National Institute for Biological Standards and Control, South Mimms, UK). Samples were pre-diluted so that serial dilutions of samples and standard dilution curves were made in parallel. The number of cells in each well was measured by the dimethylthiazol-diphenyl tetrazolium bromide (MTT) colorimetric assay . The detection limit of the assay, after considering the dilution of samples, was set at 3 international units (IU)/mL.
Epidemiological data and results of pre- and postoperative clinical examination of the study group
Gender, age, bodyweight
Postoperative clinical signs
Male, 3 months old, 2.5 kg
Obtundation, mild ataxia on all four limbs, circling, aimless barking
Mini Australian shepherd
Male-neutered, 26 months old, 12.5 kg
Visual deficits, reduced menace, circling
Visual deficits, reduced menace
Peruvian hairless dog
Male, 2 months old, 2.8 kg
Ataxia on all four limbs, ventro-lateral strabismus, obtundation
Male, 54 months old, 20 kg
Obtundation, circling, head tremor, hypermetria in the front limbs
Cavalier King Charles spaniel
Male neutered, 60 months old, 9.9 kg
Male, 21 months old, 9.2 kg
Obtundation, ataxia on all four limbs
Female, 7 months old 3.4 kg
Obtundation, ataxia, head tilt tremor
Male neutered, 3 months old, 1.2 kg
Obtundation, mild ataxia, spasticity in all four limbs, reduced menace response
Male, 4 months old, 13.9 kg
Visual deficits. reduced menace, nystagmus, hypoactive
Visual deficits, reduced menace
Jack Russell terrier
Male, 4 months old, 4.7 kg
Obtundation, ataxia on all four limbs
Female, 25 months old 12.5 kg
Intermittent obtundation, head pressing
Male neutered, 6 months old, 6.1 kg
After assessment of the normal distribution of this data using the Shapiro–Wilk test, one-way ANOVA was used to test for global differences between the mean concentration and total AQP4 quantity as well as the ventricular volume before and after surgery. If significant differences between the groups were present, post hoc Tukey`s test for multiple comparisons was used to reveal differences between all pairs of groups. IL-6 concentration and total IL-6 quantity were not normally distributed. They were tested for global differences using a Kruskal–Wallis test followed by a post hoc Dunn’s multiple comparison test.
Correlation between AQP4 and IL-6 concentration in the preoperative CSF specimen was tested using Spearman`s correlation. Association of AQP4 and IL-6 with ventricular reduction was tested using the Chi square test. P values less than 0.05 were considered to be statistically significant (95 % confidence interval).
Animals and clinical examination
Breed, age, sex, clinical signs and duration of clinical signs are summarised in Table 1 (Study group dogs) and Table 3 (Control dogs). Two dogs were excluded from the study group because there was no postoperative reduction of ventricular volume.
Pre and post-operative concentrations for aquaporin 4 and interleukin 6 and CSF volumes for dogs with hydrocephalus
Routine CSF examination
Pre-operative values AQP4 (ng/mL), total AQP4 (ng), IL-6 (IU/mL) total IL-6 (IU), CSF volume (mL)
Postoperative values AQP4 (ng/mL), total AQP4 (ng), IL-6 (IU/mL), total IL-6 (IU), CSF volume (mL)
Protein 252 mg/L
Total AQP4 quantity 301.5
Total IL-6 quantity 1486.8
CSF volume 23.6
Total AQP4 quantity 28.51
Total IL-6 quantity 84
CSF volume 2.8
Protein 276 mg/L
Total AQP4 quantity 223.5
Total IL-6 quantity 2260.8
CSF volume 26.4
Total AQP4 quantity 27.99
Total IL-6 quantity 96.62
CSF volume 2.6
Protein 276 mg/L
Total AQP4 quantity 391.33
Total IL-6 quantity 492.8
CSF volume 22.4
Total AQP4 quantity 150
Total IL-6 quantity 61.1
CSF volume 10.6
Protein 240 mg/L
Total AQP4 quantity 455.56
Total IL-6 quantity 834.4
CSF volume 29.8
Total AQP4 quantity 45.62
Total IL-6 quantity 634.5
CSF volume 4.7
Protein 240 mg/L
Total AQP4 quantity 278.3
Total IL-6 quantity 803.4
CSF volume 20.6
Total AQP4 quantity 34.45
Total IL-6 quantity 136.5
CSF volume 6.5
Protein 208 mg/L
Total AQP4 quantity 133.3
Total IL-6 quantity 658.41
CSF volume 12.91
Total AQP4 quantity 63.67
Total IL-6 quantity 205.76
CSF volume 6.43
Total AQP4 quantity 467.67
Total IL-6 quantity 2265.48
CSF volume 26.04
Total AQP4 quantity 21.43
Total IL-6 quantity 88.8
CSF volume 2.4
Protein 246 mg/L
Total AQP4 quantity 211.54
Total IL-6quantity 1078.8
CSF volume 17.4
Total AQP4 quantity 3.95
Total IL-6 quantity 13.4
CSF volume 1.64
Total AQP4 quantity 472.45
Total IL-6 quantity 1709.5
CSF volume 26.3
Total AQP4 quantity 58.03
Total IL-6 quantity 260
CSF volume 6.5
Protein 300.9 mg/L
Total AQP4 quantity 675.31
Total IL-6 quantity 2323.2
CSF volume 35.2
Total AQP4 quantity 190.95
Total IL-6 quantity 1362.75
Protein 374 mg/L
Total AQP4 quantity 168.85
Total IL-6 quantity 623.16
CSF volume 11.54
Total AQP4 quantity 58.31
Total IL-6 quantity 162
CSF volume 3.6
Protein 204 mg/L
Total AQP4 quantity 130.14
Total IL-6 quantity 1631
CSF volume 18.33
Total AQP4 quantity 42.93
Total IL-6 quantity 438.84
CSF volume 9.54
Epidemiological data and CSF analysis in the control group
Breed, age, gender, body weight
Routine CSF examination
CSF volume (mL)
AQP4 concentrations and total quantity
IL-6 concentrations and total quantity
Pug, 4 years male neutered, 4.6 kg
Protein 262 mg/L
Total AQP4 quantity 27
IL-6: 25 IU
Total IL-6 quantity 60
Dachshund, 9 years, male, 6 kg
Protein 256 mg/L
Total AQP4 quantity 30.94
IL-6: 24 IU
Total IL-6 quantity 76.8
Austrian hound, 3 years male, 26 kg
Protein 220 mg/L
Total AQP4 quantity 28.26
IL-6: 27 IU
Total IL-6 quantity 85.87
German Shepherd dog, male, 5 years, 22 kg
Protein 302 mg/L
Total AQP4 quantity 51.78
IL-6: 19 IU
Total IL-6 quantity 79.8
Beagle, male-neutered 2 years, 12 kg
Protein 286 mg/L
Total AQP4 quantity 21.74
IL-6: 42 IU
Total IL-6 quantity 102.9
Doberman, male, 4 years, 36 kg
Protein 120 mg/L
Total AQP4 quantity 19.97
IL-6: 20 IU
Total IL-6 quantity 60.8
French Bulldog female-neutered, 1,5 years, 8 kg
Protein 79 mg/L
Total AQP4 quantity 30.60
IL-6: 27 IU
Total IL-6 quantity 91.8
Bernese mountain dog, female, 6 years, 34 kg
Protein 265 mg/L
Total AQP4 quantity 47.86
IL-6: 22 IU
Total IL-6 quantity 88
Cavalier King Charles spaniel, female, 8 years, 6 kg
Protein 289 mg/L
Total AQP4 quantity 36.87
IL-6: 34 IU
Total IL-6 quantity 108.8
Doberman, female- neutered, 7 years, 29 kg
Protein 156 mg/L
Total AQP4 quantity 25.79
IL-6: 55 IU
Total IL-6 quantity 176.55
Total AQP4 quantities were globally different between groups (P < 0.0001). The mean total AQP4 quantity (325.8 ng) in dogs with internal hydrocephalus before surgery was significantly different from control dogs (32.12 ng, P < 0.0001). After shunting, mean total AQP4 quantity was significantly different from pre-operative values (60.49 ng, P < 0.0001), but not different from controls (P > 0.05). CSF volume was significantly reduced after surgery (P < 0.001). A reduction of ventricular volume was associated with AQP4 decrease (P < 0.001).
AQP1 levels remained below the detection limit in all CSF samples analysed. Using an AQP1 ELISA kit and the same procedure as for AQP4, OD values were around zero.
IL-6 concentrations (Fig. 4) were globally different between the groups (P < 0.0036). The median IL-6 concentrations before surgery (62 IU/mL) was significantly higher than postoperative values (34 IU/mL; P < 0.001) and higher when compared to controls (26 IU/mL; P < 0.001). Postoperative values were not different to controls (P > 0.05). Total IL-6 quantities were significantly different between groups (P < 0.0001). Total IL-6 quantities were significantly higher in dogs with internal hydrocephalus than in control dogs before surgery (1083 vs. 86.3 IU; P < 0.0001) and significantly decreased after shunting (149.3 IU; P < 0.0001), but were still significantly higher than in the control group (P < 0.01).
Concentrations of AQP4 and IL-6 measured in the preoperative CSF specimens were not correlated (P = 0.449).
We found increased AQP4 and IL-6 concentrations in the CSF of dogs with idiopathic communicating hydrocephalus. AQP4 and IL-6 concentrations decreased significantly after reduction of lateral ventricular volume using an indwelling ventriculo-peritoneal shunt system. Up-regulation of AQP4 channels has been documented in a variety of pathological processes in the brain that result in fluid overload, including internal hydrocephalus. In rats with inherited  and kaolin-induced hydrocephalus , an increase in AQP4 mRNA- and protein levels within the periventricular parenchyma was reported post-induction. It seems likely that the increase in AQP4 reflects the development of an alternative pathway for parenchymal CSF absorption [9, 15–17, 19, 20]. This notion is also supported by the observation that AQP4 null mice exhibit a more severe form of hydrocephalus with larger ventricular distension and pressure elevation after kaolin injection, than mice with unimpaired AQP4 expression . Whereas AQP4 changes have been well described in experimentally-induced hydrocephalus, few publications have studied the association between AQPs and naturally-occurring hydrocephalus. This is important in that hydrocephalus is usually non-communicating in laboratory rodents, but communicating in the dogs reported in the present study. Hence, there are more similarities between human and canine communicating hydrocephalus, when compared to experimentally-induced hydrocephalus after intrathecal kaolin injection in rodents and the subsequent inflammatory reaction. It has been shown in dogs with induced hydrocephalus that after an initial rise, CSF pressure can return to normal levels as the ventricles enlarge .
In the classic model of CSF physiology in dogs the fluid is produced by the choroid plexus . The primary sites of reabsorption are the arachnoid projections from the subarachnoid space into the sagittal dural venous sinus. There is evidence that extracellular fluid (ECF) from the brain parenchyma essentially contributes to CSF production and its bulk flow within the central nervous system . Under normal conditions, arterial pulsation drives the ECF toward the veins and towards the ventricles in humans and dogs. It has been suggested that this physiological ECF flow is reduced in hydrocephalus, and the pericapillary space has been confirmed as playing a critical role in the reabsorption of ECF [9, 33]. The ependymal lining is frequently destroyed in hydrocephalus  and AQP4 can, therefore, leak more easily from the parenchyma to the CSF via the ECF .
It remains unclear however, whether the increased AQP4 levels in the CSF of hydrocephalic dogs and humans is an unspecific finding related simply to the destruction of cell membranes. In this scenario, on the one hand, an increase of AQP4 would be a pure epiphenomenon reflecting damage to the structural integrity of the ependyma  and periventricular white matter. This might be the more likely cause of the increase in AQP4 in the CSF. On the other hand, it has also been suggested that higher AQP4 levels could also be a reflection of increased production and turnover of the protein and its release into the interstitial space and ventricular system. Such shedding of membrane proteins has been documented for renal AQPs. Wen et al.  showed that urinary excretion of AQP2 occurs under physiological conditions as part of its increased integration into the apical membrane of the collecting duct after vasopressin stimulation. During this process AQP2 is excreted into the urine in a proportion specific to the quantity of membrane-bound AQP [37–40].
It has been shown that distension of the ventricles and compression of periventricular white matter capillaries are accompanied by pro-inflammatory cytokine activation. Damage to the periventricular white matter is the main impact on brain integrity in hydrocephalus cases [34, 41]. IL-6 has been associated with periventricular white matter injury in newborn babies with peripartal hypoxia  and increases in IL-6 and IL-8 were more pronounced in the infants with a severe clinical course . A correlation between IL-6 levels and white matter integrity has been documented in elderly humans [43, 44]. We therefore consider that changes in IL-6 concentrations in the CSF act as a surrogate marker for white matter injury in the present study. Here, it has become evident that AQP4 concentration was not correlated with IL-6 concentration in CSF taken preoperatively. This observation might favour the notion that CSF AQP4 level does not merely reflect white matter damage, however, the exact circumstances between pressure rise and AQP4 changes in the CSF remain to be further analysed in future studies.
Our study also showed that adjusting the concentrations of AQP4 and IL-6 to the total CSF volume was not necessary to detect significant differences in AQP4 and IL-6 concentrations. Following the rationale that CSF is constantly produced and the amount of the solute may depend on the amount of the total solvent (CSF), we considered it might be necessary to calculate AQP4 and IL-6 total quantities by multiplying by the ventricular volume. Although preoperative volumes in some dogs exceeded three times the volume of other hydrocephalic dogs, the differences in ventricular dimensions did not obscure differences in CSF AQP4 concentrations. In fact, the concentrations were comparable to those measured in children with hydrocephalus (13.3 in dogs vs. 11.32.ng/mL in children), as well as those in normal dogs to the values in unaffected children (9.5 in dogs vs. 8.61 ng/mL in children) .
The main limitation of this study is therefore the heterogeneity of the examined dogs. Different dog breeds were examined without knowledge of the underlying cause of the CSF accumulation or of intraventricular pressure, with different degrees of ventricular dilatation and different durations of clinical signs. Dogs with hydrocephalus were younger than control dogs. Furthermore, CSF from the control group was taken after euthanasia and also not from the intraventricular site, which might also have a potential influence on measured AQP4 and IL-6 levels.
While we were able to measure AQP4 in the CSF of normal and hydrocephalic dogs, AQP1 levels were below the detection limit in all samples. Interestingly, analysis of AQP1 expression after the induction of hydrocephalus in rodents has revealed conflicting results. In mice, it has been shown that AQP1 is down-regulated after induction of hydrocephalus, rather suggesting a compensatory response to hydrocephalus , however, another study showed unchanged AQP1 expression in a rat model of hydrocephalus . Being confined to the choroid plexus, AQP1 expression is much lower than AQP4 expression in the rodent brain and CSF. This is also reflected in the fact that values remained below the detection limit in our current analyses for canine CSF AQP1.
An increase in ventricular dimension is accompanied by increases in AQP4 and IL-6 concentrations in the CSF of dogs with idiopathic communicating hydrocephalus. All were greatly reduced or normalised after shunt treatment. Therefore AQP4 and IL-6 in CSF can be indicators of ventriculomegaly, of cellular damage, and of improvement after the treatment of hydrocephalus. Based on the results of this study, a brain tissue-based determination of AQP4 at the mRNA and protein level might be rewarding to analyse the potential role of AQP4 in the compensation of extracellular fluid overload in dogs with communicating hydrocephalus.
MJS and NO authors helped to draft the manuscript and participated in its design. MK and JH collected the data for the study. JR analyzed the data. CR performed the statistical analysis of the data. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Shibab N, Davies E, Kenny PJ, Loderstedt S, Volk HA. Treatment of hydrocephalus with ventriculoperitoneal shunting in twelve dogs. Vet Surg. 2011;40:477–84.View ArticleGoogle Scholar
- Platt S, Garosi L. Hydrocephalus. In: Small Animal Neurological Emergencies. London: Manson Publishing Ltd/The Veterinary Press; 2012. p. 116–7.
- Biel M, Kramer M, Forterre F, Jurina K, Failing K, Schmidt MJ. Outcome of ventriculoperitoneal shunt implantation for treatment of congenital internal hydrocephalus in dogs and cats: 36 cases (2001–2009). J Am Vet Med Assoc. 2013;242:948–58.View ArticlePubMedGoogle Scholar
- Cinalli G, Maixner WJ, Sainte-Rose CJ. Shunt hardware and surgical technique In: Pediatric Hydrocephalus. Springer: New York; 2004, p. 295–315.
- Kolecka M, Ondreka N, Moritz A, Kramer M, Schmidt MJ. Effect of acetazolamide and subsequent ventriculo-peritoneal shunting on clinical signs and ventricular volumes in dogs with internal hydrocephalus. Acta Vet Scand. 2015;57:49.View ArticlePubMedPubMed CentralGoogle Scholar
- Kennedy CR, Ayers S, Campbell MJ, Elbourne D, Hope P, Johnson A. Randomized controlled trial of acetazolamide and furosemide in posthemorrhagic ventricular dilation in infancy: follow-up at 1 year. Pediatrics. 2001;108:597–607.View ArticlePubMedGoogle Scholar
- Girod M, Allerton F, Gommeren K, Tutunaru AC, de Marchin J, Van Soens I, Ramery E, Peeters D. Evaluation of the effect of oral omeprazole on canine cerebrospinal fluid production: a pilot study. Vet J. 2016;209:119–24.View ArticlePubMedGoogle Scholar
- Yool A. Aquaporins: multiple roles in the central nervous system. Neuroscientist. 2007;13:470–85.View ArticlePubMedGoogle Scholar
- Neuroscience Nedergaard M. Garbage truck of the brain. Science. 2013;28:1529–30.Google Scholar
- Abbott NJ. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Intern. 2004;45:545–52.View ArticleGoogle Scholar
- Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci. 2013;14:265–77.View ArticlePubMedPubMed CentralGoogle Scholar
- Vizuete ML, Venero JL, Vargas C, Ilundáin AA, Echevarría M, Machado A, Cano J. Differential upregulation of aquaporin-4 mRNA expression in reactive astrocytes after brain injury: potential role in brain edema. Neurobiol Dis. 1999;6:245–58.View ArticlePubMedGoogle Scholar
- Deng J, Zhao F, Yu X, Zhao Y, Li D, Shi H, Sun Y. Expression of aquaporin 4 and breakdown of the blood-brain barrier after hypoglycemia-induced brain edema in rats. PLoS ONE. 2014;9(9):e107022. doi:10.1371/journal.pone.0107022.View ArticlePubMedPubMed CentralGoogle Scholar
- Vella J, Zammit C, Digiovanni G, Muscat R, Valentino M. The central role of aquaporins in the pathophysiology of ischemic stroke. Front Cell Neurosci. 2015;9:108.View ArticlePubMedPubMed CentralGoogle Scholar
- Mao X, Enno TL, Del Bigio MR. Aquaporin 4 changes in rat brain with severe hydrocephalus. Eur J Neurosci. 2006;23:2929–36.View ArticlePubMedGoogle Scholar
- Skjolding AD, Rowland IJ, Søgaard LV, Praetorius J, Penkowa M, Juhler M. Hydrocephalus induces dynamic spatiotemporal regulation of aquaporin-4 expression in the rat brain. Cerebrospinal Fluid Res. 2010;7:20.View ArticlePubMedPubMed CentralGoogle Scholar
- Skjolding AD, Holst AV, Broholm H, Laursen H, Juhler M. Differences in distribution and regulation of astrocytic aquaporin-4 in human and rat hydrocephalic brain. Neuropathol Appl Neurobiol. 2012;39:171–90.Google Scholar
- Castañeyra-Ruiz L, González-Marrero I, González-Toledo JM, Castañeyra-Ruiz A, de Paz-Carmona H, Castañeyra-Perdomo A, et al. Aquaporin-4 expression in the cerebrospinal fluid in congenital human hydrocephalus. Fluid Barriers CNS. 2013;10:18.View ArticleGoogle Scholar
- Shen XQ, Miyajima M, Ogino I, Arai H. Expression of the water-channel protein aquaporin 4 in the H-Tx rat: possible compensatory role in spontaneously arrested hydrocephalus. J Neurosurg. 2006;105:459–64.PubMedGoogle Scholar
- Tourdias T, Dragonu I, Fushimi Y, Deloire MSA, Boiziau C, Brochet B, et al. Aquaporin 4 correlates with apparent diffusion coefficient and hydrocephalus severity in the rat brain: a combined MRI-histological study. Neuroimage. 2009;47:659–66.View ArticlePubMedGoogle Scholar
- Kalani MY, Filippidis AS, Rekate H. Hydrocephalus and aquaporins: the role of aquaporin-1. Acta Neurochirurg. 2012;113:51–4.View ArticleGoogle Scholar
- Kaur C, Ling EA. Periventricular white matter damage in the hypoxic neonatal brain: role of microglial cells. Progr Neurobiol. 2009;87:264–80.View ArticleGoogle Scholar
- Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 2012;8(9):1254–66.View ArticlePubMedPubMed CentralGoogle Scholar
- Laubner S, Ondreka N, Failing K, Kramer M, Schmidt MJ. Magnetic resonance imaging signs of high intraventricular pressure—comparison of findings in dogs with clinically relevant internal hydrocephalus and asymptomatic dogs with ventriculomegaly. BMC Vet Sci. 2015;11:181.View ArticleGoogle Scholar
- Cinalli G, Maixner WJ, Sainte-Rose CJ. Classification and defnition of hydrocephalus. In: Pediatric Hydrocephalus. Springer: New York; 2004, p. 95–112.
- Schmidt MJ, Oelschläger HA, Haddad D, Purea A, Haase A, Kramer M. Visualizing premature brain using 17.6 Tesla magnetic resonance imaging (magnetic resonance microscopy). Vet J. 2009;182:215–22.View ArticlePubMedGoogle Scholar
- Roth J, Martin D, Störr B. Zeisberger E Neutralization of pyrogen-induced tumour necrosis factor by its type 1 soluble receptor in guinea-pigs: effects on fever and interleukin-6 release. J Physiol. 1998;509(Pt 1):267–75.View ArticlePubMedPubMed CentralGoogle Scholar
- Moeniralam HS, Bemelman WA, Endert E, Koopmans R, Sauerwein HP, Romijn JA. The decrease in nonsplenic interleukin-6 (IL-6) production after splenectomy indicates the existence of a positive feedback loop of IL-6 production during endotoxemia in dogs. Infect Immun. 1997;65(6):2299–305.PubMedPubMed CentralGoogle Scholar
- Bloch O, Auguste KI, Manley GT, Verkman AS. Accelerated progression of kaolin induced hydrocephalus in aquaporin-4-deficient mice. J Cer Blood Flow Metab. 2006;26:1527–37.View ArticleGoogle Scholar
- James AE, Burns B, Flor WF, Strecker EP, Merz T, Bush M, et al. Pathophysiology of chronic communicating hydrocephalus in dogs (Canis familiaris). Experimental studies. J Neurol Sci. 1975;24:151–78.View ArticlePubMedGoogle Scholar
- De Lahunta A, Glass EN. Cerebrospinal fluid and hydrocephalus. In: Veterinary neuroanatomy and clinical neurology. 3rd edn. Saunders: St. Louis; 2009. p.78–101.
- Brinker T, Stopa E, Morrison J, Klinge P. A new look at cerebrospinal fluid circulation. Fluids Barriers CNS. 2014;11:10.View ArticlePubMedPubMed CentralGoogle Scholar
- Page LK. Cerebrospinal fluid and extracellular fluid: their relationship to pressure and duration of canine hydrocephalus. Childs Nerv Syst. 1985;1:12–7.View ArticlePubMedGoogle Scholar
- Del Bigio MR. Neuropathological changes caused by hydrocephalus. Acta Neuropath. 1993;85:573–85.View ArticlePubMedGoogle Scholar
- Li X, Kong H, Wu W, Xiao M, Sun X, Hu G. AQP4 maintains ependymal integrity in adult mice. Neuroscience. 2009;162:67–77.View ArticlePubMedGoogle Scholar
- Wen H, Frokiaer J, Kwon TH, Nielsen S. Urinary excretion of aquaporin-2 in rat is mediated by a vasopressin-dependent apical pathway. J Am Soc Nephrol. 1999;10:1416–29.PubMedGoogle Scholar
- Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature. 1993;361:549–52.View ArticlePubMedGoogle Scholar
- Kanno K, Sasaki S, Hirata Y, Ishikawa S, Fushimi K, Nakanishi S, et al. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. New England J Med. 1995;332:1540–5.View ArticleGoogle Scholar
- Sasaki S, Fushimi K, Saito H. Cloning, characterization and chromosomal mapping of human aquaporin of collecting duct. J Clin Invest. 1994;93:1250–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Saito T, Ishikawa SE, Ando F, Okada N, Nakamura T, Kusaka I, et al. Exaggerated urinary excretion of aquaporin-2 in the pathological state of impaired water excretion dependent upon arginine vasopressin. J Clin Endocrinol Metab. 1998;83:4034–40.PubMedGoogle Scholar
- Wang D, Nykanen M, Yang N, Winlaw D, North K, Verkman AS, Owler BK. Altered cellular localization of aquaporin-1 in experimental hydrocephalus in mice and reduced ventriculomegaly in aquaporin-1 deficiency. Mol Cell Neurosci. 2011;46:318–24.View ArticlePubMedGoogle Scholar
- Savman K, Blennow M, Gustafson K, Tarkowski E, Hagberg H. Cytokine response in cerebrospinal fluid after birth asphyxia. Pediatric Res. 1998;43:746–51.View ArticleGoogle Scholar
- Nagai K, Kozaki K, Sonohara K, Akishita M, Toba K. Relationship between interleukin-6 and cerebral deep white matter and periventricular hyperintensity in elderly women. Geriatr Geront Int. 2011;11:328–32.View ArticleGoogle Scholar
- Bettcher BM, Watson CL, Walsh CM, Lobach IV, Neuhaus J, Miller JW, et al. Interleukin-6, age, and corpus callosum integrity. PLoS ONE. 2004;4(9):e106521.Google Scholar